DK1314431T3 - Oprensede sammensætninger af Newcastle disease virus - Google Patents

Oprensede sammensætninger af Newcastle disease virus

Info

Publication number: DK1314431T3
Authority: DK; Denmark
Prior art keywords: disease virus; newcastle disease; purified compositions; mammal; treating cancer
Prior art date: 1993-04-30

Application number

DK02026340T

Other languages

English (en)

Inventor

Robert M Lorence

Kirk W Reichard

Original Assignee

Wellstat Biologics Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1993-04-30

Filing date

1994-04-29

Publication date

2008-11-10

1994-04-29 Application filed by Wellstat Biologics Corp filed Critical Wellstat Biologics Corp

2008-11-10 Application granted granted Critical

2008-11-10 Publication of DK1314431T3 publication Critical patent/DK1314431T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Microbiology (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Epidemiology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biotechnology (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Analytical Chemistry (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK02026340T 1993-04-30 1994-04-29 Oprensede sammensætninger af Newcastle disease virus DK1314431T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US5551993A	1993-04-30	1993-04-30
PCT/US1994/004732 WO1994025627A1 (en)	1993-04-30	1994-04-29	Methods of treating and detecting cancer using viruses

Publications (1)

Publication Number	Publication Date
DK1314431T3 true DK1314431T3 (da)	2008-11-10

Family

ID=21998395

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK02026340T DK1314431T3 (da)	1993-04-30	1994-04-29	Oprensede sammensætninger af Newcastle disease virus
DK04017349T DK1486211T3 (da)	1993-04-30	1994-04-29	Sammensætninger til behandling af cancer ved anvendelse af vira
DK94916604T DK0696326T5 (da)	1993-04-30	1994-04-29	Anvendelse af NDV til fremstilling af et medikament til behandling af cancer

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK04017349T DK1486211T3 (da)	1993-04-30	1994-04-29	Sammensætninger til behandling af cancer ved anvendelse af vira
DK94916604T DK0696326T5 (da)	1993-04-30	1994-04-29	Anvendelse af NDV til fremstilling af et medikament til behandling af cancer

Country Status (12)

Country	Link
US (2)	US7056689B1 (da)
EP (4)	EP1486211B1 (da)
JP (3)	JP4338781B2 (da)
AT (3)	ATE236271T1 (da)
AU (1)	AU699487B2 (da)
CA (1)	CA2161671A1 (da)
DE (3)	DE69432409T2 (da)
DK (3)	DK1314431T3 (da)
ES (3)	ES2315595T3 (da)
HK (1)	HK1052871A1 (da)
PT (3)	PT1314431E (da)
WO (1)	WO1994025627A1 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE69432409T2 (de) *	1993-04-30	2003-12-24	Wellstat Biologics Corp., Gaithersburg	Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
CA2305269C (en)	1997-10-09	2012-07-03	Pro-Virus, Inc.	Treatment of neoplasms with viruses
WO2000062735A2 (en) *	1999-04-15	2000-10-26	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US20030044384A1 (en)	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US7780962B2 (en)	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
US7470426B1 (en)	1997-10-09	2008-12-30	Wellstat Biologics Corporation	Treatment of neoplasms with viruses
FR2788099B1 (fr)	1999-01-06	2001-02-09	Vallourec Mannesmann Oil & Gas	Assemblage filete de deux tubes metalliques a couple eleve de vissage
AU2005201079C1 (en) *	1999-04-15	2008-11-06	Wellstat Biologics Corporation	Treatment of neoplasms with viruses
US8147822B1 (en)	1999-09-17	2012-04-03	Wellstat Biologics Corporation	Oncolytic virus
AUPQ425699A0 (en)	1999-11-25	1999-12-23	University Of Newcastle Research Associates Limited, The	A method of treating a malignancy in a subject and a pharmaceutical composition for use in same
US8491884B2 (en)	2000-05-03	2013-07-23	Oncolytics Biotech Inc.	Virus clearance of neoplastic cells from mixed cellular compositions
AR028039A1 (es)	2000-05-03	2003-04-23	Oncolytics Biotech Inc	Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas
US7306902B2 (en)	2002-06-28	2007-12-11	Oncolyties Biotech Inc.	Oncolytic viruses as phenotyping agents for neoplasms
IL153570A0 (en)	2000-06-26	2003-07-06	Wellstat Biologics Corp	Purging of cells using viruses
AR035227A1 (es)	2001-02-20	2004-05-05	Oncolytics Biotech Inc	Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus
NZ527687A (en)	2001-05-11	2005-10-28	Wellstat Biolog Corp Formerly	Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer
US7615209B2 (en) *	2001-09-12	2009-11-10	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Compositions of NDV and methods of use thereof for treatment of cancer
IL145397A0 (en) *	2001-09-12	2002-06-30	Yissum Res Dev Co	Compositions and methods for treatment of cancer
US20040005546A1 (en)	2002-02-28	2004-01-08	Oncolytics Biotech Inc.	Use of ribozymes in the detection of adventitious agents
CA2374388C (en)	2002-02-28	2005-07-12	Matthew C. Coffey	The use of ribozymes in the detection of adventitious agents
WO2004000209A2 (en)	2002-06-21	2003-12-31	Wellstat Biologics Corporation	Administration of therapeutic viruses
WO2004043222A2 (en) *	2002-11-05	2004-05-27	Wellstat Biologics Corporation	Treating carcinoid neoplasms with therapeuthic viruses
AU2002953436A0 (en)	2002-12-18	2003-01-09	The University Of Newcastle Research Associates Limited	A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis
US20060099189A1 (en) *	2003-03-24	2006-05-11	Lorence Robert M	Anti-cancer virus desensitization method
CN1902312B (zh) *	2003-11-04	2011-02-23	株式会社载体研究所	制备导入了基因的树突细胞的方法
US20060018884A1 (en) *	2003-11-25	2006-01-26	United Cancer Research Institute	Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent
WO2005113018A2 (en)	2004-04-27	2005-12-01	Wellstat Biologics Corporation	Cancer treatment using viruses and camptothecins
WO2006001122A1 (ja) *	2004-06-24	2006-01-05	Dnavec Research Inc.	Rnaウイルスが導入された樹状細胞を含む抗癌剤
JP5190958B2 (ja) *	2005-07-14	2013-04-24	ウェルスタットバイオロジクスコーポレイション	ウイルス、フルオロピリミジンおよびカンプトテシンを使用した癌の処置
HUE037460T2 (hu)	2005-12-02	2018-08-28	Icahn School Med Mount Sinai	Nem-natív felületi fehérjéket prezentáló kiméra Newcastle disease vírusok és alkalmazásuk
US20090175826A1 (en)	2006-06-05	2009-07-09	Elankumaran Subbiah	Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same
WO2008144067A1 (en) *	2007-05-21	2008-11-27	Board Of Regents, University Of Texas System	Methods and compositions for treatment of cancer using oncolytic rsv activity
EP2345415B1 (en) *	2008-09-16	2015-01-21	GenomIdea Inc.	Therapeutic/prophylactic agent for prostate cancer
ES2550179T3 (es)	2009-02-05	2015-11-05	Icahn School Of Medicine At Mount Sinai	Virus quiméricos de la enfermedad de Newcastle y usos de los mismos
EP2327764B1 (en)	2009-11-30	2011-12-28	United Cancer Research Institute	New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer
MY180687A (en)	2013-03-14	2020-12-07	Icahn School Med Mount Sinai	Newcastle disease viruses and uses thereof
EP3441084A1 (en)	2014-02-27	2019-02-13	Viralytics Limited	Oncolytic virus and immuno-stimulatory agent for combined use in the treatment of cancer
IL263979B2 (en)	2017-05-10	2023-09-01	Wellstat Immuno Therapeutics Llc	Viruses with an envelope resistant to the immune system for cancer treatment
JOP20190256A1 (ar)	2017-05-12	2019-10-28	Icahn School Med Mount Sinai	فيروسات داء نيوكاسل واستخداماتها

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3577525A (en)	1964-07-01	1971-05-04	Cornell Res Foundation Inc	Adenovirus vaccine against canine hepatitis
NL7111160A (da)	1971-03-09	1972-09-12
ZA754725B (en)	1974-08-01	1976-06-30	H Stickl	Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use
JPS5173117A (en) *	1974-12-19	1976-06-24	Handai Biseibutsubyo Kenkyukai	Ganryohozaino seiho
US4108983A (en)	1976-06-01	1978-08-22	The Wistar Institute	Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors
US4126671A (en)	1976-08-17	1978-11-21	Pitman-Moore, Inc.	Method for detecting bovine leukemia viral infection
US4379839A (en)	1977-05-23	1983-04-12	The Trustees Of Columbia University In The City Of New York	Method for detecting cancer
IT1117218B (it)	1979-05-18	1986-02-17	Depa Sas	Procedimento per la produzione di un prodotto per la diagnosi dei tumori delle parti molli o carcinomi e prodotto ottenuto
US4282315A (en)	1979-09-13	1981-08-04	Corning Glass Works	Preparation of enriched whole virus radioligand
US4334016A (en)	1980-06-19	1982-06-08	The Wistar Institute Of Anatomy And Biology	Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test
US4405712A (en)	1981-07-01	1983-09-20	The United States Of America As Represented By The Department Of Health And Human Services	LTR-Vectors
US4465769A (en)	1981-12-11	1984-08-14	The United States Of America As Represented By The Department Of Health And Human Services	Non-transformed thymidine kinaseless cell line and its use for testing tumorigenic potential of genes
JPS58116422A (ja)	1981-12-28	1983-07-11	Green Cross Corp:The	抗腫瘍剤
US4582787A (en)	1982-12-30	1986-04-15	Frankel Jack W	Method of testing a patient for a predisposition to lung cancer, certain other cancers, neurofibromatosis and certain other hereditary disorders
US4571385A (en)	1983-06-27	1986-02-18	The United States Of America As Represented By The Department Of Health And Human Services	Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors
US4748109A (en)	1983-07-01	1988-05-31	Baird Phillip J	Assay method and reagent to determine antibodies to papillomavirus virions
US4647773A (en)	1984-04-23	1987-03-03	The United States Of America As Represented By The Department Of Health And Human Services	Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS
JPS60249058A (ja)	1984-05-25	1985-12-09	Eisai Co Ltd	Ａｔｌウイルス抗体の測定方法および試薬
HU197846B (en)	1984-07-02	1989-06-28	Laszlo Csatary	Process for producing therapeutic composition suitable for treating virus infections
US5075213A (en)	1984-07-27	1991-12-24	City Of Hope	Method for detection and prevention of human cytomegalovirus infection
HU197517B (en)	1984-07-30	1989-04-28	Laszlo Csatary	Process for production of terapeutical composition applicable against virus infection
FR2593828B2 (fr)	1986-01-31	1990-05-04	Pasteur Institut	Sonde a papillomavirus et procede de diagnostic in-vitro d'infections a papillomavirus
US4735895A (en)	1984-12-28	1988-04-05	Oncotech, Inc.	Cancer susceptibility test
US4786590A (en)	1985-01-15	1988-11-22	California Institute Of Technology	Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis
GB8500918D0 (en)	1985-01-15	1985-02-20	Cancer Res Inst	Viral isolates
US4970071A (en)	1985-01-18	1990-11-13	Mcmichael John	Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
WO1987003451A1 (en)	1985-12-05	1987-06-18	Fred Hutchinson Cancer Research Center	Anti-sense rna for treatment of retroviral disease states
AU602875B2 (en)	1985-12-18	1990-11-01	British Technology Group Limited	Newcastle disease virus gene clones
US4839288A (en)	1986-01-22	1989-06-13	Institut Pasteur	Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes
US4861719A (en)	1986-04-25	1989-08-29	Fred Hutchinson Cancer Research Center	DNA constructs for retrovirus packaging cell lines
US4861720A (en)	1986-07-03	1989-08-29	Regents Of The University Of California	Oncornavirus vaccines and feline alpha-type interferon
NZ224567A (en) *	1987-05-19	1990-08-28	Yissum Res Dev Co	Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil
US4849334A (en)	1987-06-09	1989-07-18	Life Technologies, Inc.	Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same
US4908306A (en)	1987-06-12	1990-03-13	Life Technologies, Inc.	Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same
DE3722968A1 (de)	1987-07-11	1989-01-19	Behringwerke Ag	Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine
CA1341439C (en)	1987-08-26	2003-09-23	Niels C. Pedersen	Feline t-lymphotropic lentivirus
EP0331939B1 (en)	1988-02-16	2001-11-14	Greatbatch Gen-Aid, Ltd	Modified cells having resistance to retroviral infection
DE3806565A1 (de)	1988-03-01	1989-09-14	Deutsches Krebsforsch	Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen
US5077198A (en)	1988-04-14	1991-12-31	Eastman Kodak Company	Diagnostic kit and method for rapid detection of antibodies
US5124148A (en)	1988-04-27	1992-06-23	United Cancer Research Institute	Method for treating viral diseases with attenuated virus
US5215745A (en)	1988-04-27	1993-06-01	United Cancer Research Institute	Method for treating viral diseases with attenuated virus
FR2632956B2 (fr)	1988-05-13	1991-07-12	Pasteur Institut	Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus
US5192539A (en)	1988-07-21	1993-03-09	Akzo N.V.	Infectious bursal disease virus production in continuous cell lines
US5057314A (en)	1988-09-30	1991-10-15	Whitfill Craig E	Low molecular weight antiviral factors
FR2639225B1 (fr)	1988-11-21	1993-05-21	Centre Nat Rech Scient	Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines
US5045447A (en)	1989-03-15	1991-09-03	Minson Anthony C	Method of producing antibodies to HPV
US5169753A (en)	1989-06-05	1992-12-08	Genelabs Incorporated	Method and kit for detecting human retrovirus
FR2656627B1 (fr)	1989-12-28	1992-04-17	Pasteur Institut	Sonde a papillomavirus (hvpv63), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus.
CN1054192A (zh) *	1990-02-26	1991-09-04	张炳团	人体内诱导干扰素的制造方法
US5739107A (en) *	1991-03-11	1998-04-14	Creative Biomolecules, Inc.	Morphogen treatment of gastrointestinal ulcers
US5252479A (en)	1991-11-08	1993-10-12	Research Corporation Technologies, Inc.	Safe vector for gene therapy
US5195539A (en) *	1992-03-23	1993-03-23	Minnesota Mining And Manufacturing Company	Earplug compression device
CA2132328C (en)	1992-03-24	2000-10-31	Laszlo K. Csatary	Vaccine containing live virus for therapy of viral diseases and malignancies
EP0931830B1 (en)	1993-02-16	2001-03-07	Onyx Pharmaceuticals, Inc.	Cytopathic viruses for therapy and phophylaxis of neoplasia
KR960701208A (ko)	1993-03-16	1996-02-24	엔 엔 데이비스	바이러스 단백질에 의해 면역 반응을 자극하는 방법(stimulation of immune response by viral protein)
DE69432409T2 (de) *	1993-04-30	2003-12-24	Wellstat Biologics Corp., Gaithersburg	Verwendung der NDV zur Herstellung eines Medikaments zur Krebsbehandlung
US20030044384A1 (en) *	1997-10-09	2003-03-06	Pro-Virus, Inc.	Treatment of neoplasms with viruses
US7780962B2 (en) *	1997-10-09	2010-08-24	Wellstat Biologics Corporation	Treatment of neoplasms with RNA viruses
WO2004043222A2 (en) *	2002-11-05	2004-05-27	Wellstat Biologics Corporation	Treating carcinoid neoplasms with therapeuthic viruses

1994
- 1994-04-29 DE DE69432409T patent/DE69432409T2/de not_active Expired - Lifetime
- 1994-04-29 EP EP04017349A patent/EP1486211B1/en not_active Expired - Lifetime
- 1994-04-29 EP EP94916604A patent/EP0696326B1/en not_active Expired - Lifetime
- 1994-04-29 PT PT02026340T patent/PT1314431E/pt unknown
- 1994-04-29 PT PT04017349T patent/PT1486211E/pt unknown
- 1994-04-29 AT AT94916604T patent/ATE236271T1/de not_active IP Right Cessation
- 1994-04-29 JP JP52456394A patent/JP4338781B2/ja not_active Expired - Fee Related
- 1994-04-29 DK DK02026340T patent/DK1314431T3/da active
- 1994-04-29 EP EP02026340A patent/EP1314431B1/en not_active Expired - Lifetime
- 1994-04-29 AU AU68213/94A patent/AU699487B2/en not_active Ceased
- 1994-04-29 DE DE69435118T patent/DE69435118D1/de not_active Expired - Lifetime
- 1994-04-29 PT PT94916604T patent/PT696326E/pt unknown
- 1994-04-29 AT AT04017349T patent/ATE411809T1/de not_active IP Right Cessation
- 1994-04-29 EP EP08166836A patent/EP2009119A1/en not_active Withdrawn
- 1994-04-29 ES ES04017349T patent/ES2315595T3/es not_active Expired - Lifetime
- 1994-04-29 AT AT02026340T patent/ATE401092T1/de not_active IP Right Cessation
- 1994-04-29 DK DK04017349T patent/DK1486211T3/da active
- 1994-04-29 ES ES02026340T patent/ES2310580T3/es not_active Expired - Lifetime
- 1994-04-29 CA CA002161671A patent/CA2161671A1/en not_active Abandoned
- 1994-04-29 WO PCT/US1994/004732 patent/WO1994025627A1/en active IP Right Grant
- 1994-04-29 DE DE69435155T patent/DE69435155D1/de not_active Expired - Lifetime
- 1994-04-29 ES ES94916604T patent/ES2196026T3/es not_active Expired - Lifetime
- 1994-04-29 DK DK94916604T patent/DK0696326T5/da active
- 1994-06-16 US US08/260,536 patent/US7056689B1/en not_active Expired - Lifetime
2003
- 2003-07-12 HK HK03105047.9A patent/HK1052871A1/zh unknown
2005
- 2005-03-24 JP JP2005087342A patent/JP2005187484A/ja not_active Withdrawn
2006
- 2006-05-26 US US11/441,201 patent/US7736640B2/en not_active Expired - Fee Related
2009
- 2009-03-26 JP JP2009077773A patent/JP2009149689A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP1314431A3 (en)	2003-06-18
DE69435155D1 (de)	2008-12-04
AU699487B2 (en)	1998-12-03
WO1994025627A1 (en)	1994-11-10
JP2009149689A (ja)	2009-07-09
EP2009119A1 (en)	2008-12-31
EP1486211A1 (en)	2004-12-15
PT1486211E (pt)	2009-02-02
DK1486211T3 (da)	2009-01-19
EP1314431A2 (en)	2003-05-28
ATE411809T1 (de)	2008-11-15
US7736640B2 (en)	2010-06-15
ATE236271T1 (de)	2003-04-15
EP1486211B1 (en)	2008-10-22
JP4338781B2 (ja)	2009-10-07
HK1052871A1 (zh)	2003-10-03
DK0696326T3 (da)	2003-06-23
PT1314431E (pt)	2008-10-24
EP1314431B1 (en)	2008-07-16
US7056689B1 (en)	2006-06-06
EP0696326A1 (en)	1996-02-14
EP0696326B1 (en)	2003-04-02
ATE401092T1 (de)	2008-08-15
JP2005187484A (ja)	2005-07-14
DE69432409T2 (de)	2003-12-24
AU6821394A (en)	1994-11-21
DE69435118D1 (de)	2008-08-28
ES2310580T3 (es)	2009-01-16
ES2196026T3 (es)	2003-12-16
DK0696326T5 (da)	2003-07-14
CA2161671A1 (en)	1994-11-10
PT696326E (pt)	2003-08-29
DE69432409D1 (de)	2003-05-08
JPH09503995A (ja)	1997-04-22
US20060216310A1 (en)	2006-09-28
ES2315595T3 (es)	2009-04-01
EP0696326A4 (en)	1997-08-20

Publication	Publication Date	Title
DK1314431T3 (da)	2008-11-10	Oprensede sammensætninger af Newcastle disease virus
EP0313305A3 (en)	1990-02-07	Photoprotection compositions comprising chelating agents
DK0607389T3 (da)	1998-04-06	Bearbejdelige, cementbaserede sammensætninger
FI943749A0 (fi)	1994-08-15	Taksaanijohdannaisten fosfono-oksimetyylieetterit
DE69109351D1 (de)	1995-06-08	Antimikrobielle Zusammensetzung.
FI956228L (fi)	1995-12-22	Sisäänhengitykseen tarkoitettuja koostumuksia
FI921491L (fi)	1992-04-03	Antimalariakompositioner.
NO911861D0 (no)	1991-05-14	Stabilisert fgf-sammensetning.
FI915315L (fi)	1992-05-15	Silikatkomposition.
ATE263187T1 (de)	2004-04-15	Neuartige heparin bindende peptide
FI914255L (fi)	1992-03-18	I uv-ljus haerdbar organopolysil- oxankomposition.
NO912598D0 (no)	1991-07-02	Hypokalori-matsammensetning.
BR9402143A (pt)	1995-03-07	Composto, composição e uso
FI922583L (fi)	1992-12-06	Cerium(4)oxidbaserad komposition, dess framstaellning och anvaendning
DE69201714D1 (de)	1995-04-20	Lichtabsorbierende, dielektrische Zusammensetzungen.
DE68913950D1 (de)	1994-04-21	Stabilisierte, Schwefel lösende Zusammensetzungen.
EP0624627A3 (en)	1995-03-01	Radiation-curable organopolysiloxane composition.
BR9408158A (pt)	1997-08-05	Composto de triazina e composição curável
EA200400670A1 (ru)	2004-10-28	Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи
DE59104744D1 (de)	1995-04-06	Neue härtbare Zusammensetzungen.
DE69016547D1 (de)	1995-03-16	Hochschlagfeste Polyolefinzusammensetzungen.
AR009461A1 (es)	2000-04-26	Composiciones para controlar hongos daninos y metodo para controlar hongos daninos con dichas composiciones.
DE69102501D1 (de)	1994-07-21	Fluoreszente Zusammensetzung für Elektronenstrahlanregung mit niedriger Geschwindigkeit.
DE59102477D1 (de)	1994-09-15	Schmierstoffzusammensetzung.
DE59101570D1 (de)	1994-06-09	Schmierstoffzusammensetzung.